These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36053786)

  • 21. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.
    Bowers JT; Anna J; Bair SM; Annunzio K; Epperla N; Pullukkara JJ; Gaballa S; Spinner MA; Li S; Messmer MR; Nguyen J; Ayers EC; Wagner CB; Hu B; Di M; Huntington SF; Furqan F; Shah NN; Chen C; Ballard HJ; Hughes ME; Chong EA; Nasta SD; Barta SK; Landsburg DJ; Svoboda J
    Blood Adv; 2023 Nov; 7(21):6630-6638. PubMed ID: 37595053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limited-stage Hodgkin lymphoma: optimal chemotherapy and the role of radiotherapy.
    Bartlett NL
    Am Soc Clin Oncol Educ Book; 2013; ():374-80. PubMed ID: 23714551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
    Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
    Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma.
    Choi Y; Diefenbach CS
    Expert Rev Hematol; 2019 Oct; 12(10):801-808. PubMed ID: 31432732
    [No Abstract]   [Full Text] [Related]  

  • 25. Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom.
    Bröckelmann PJ; McMullen S; Wilson JB; Mueller K; Goring S; Stamatoullas A; Zagadailov E; Gautam A; Huebner D; Dalal M; Illidge T
    Br J Haematol; 2019 Jan; 184(2):202-214. PubMed ID: 30239982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD).
    Sekiguchi Y; Iizuka H; Takizawa H; Sugimoto K; Sakajiri S; Inano T; Fukuda Y; Shirane S; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Sekiguchi N; Noguchi M
    Intern Med; 2020 Sep; 59(17):2165-2171. PubMed ID: 32461524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.
    Böll B; Goergen H; Behringer K; Bröckelmann PJ; Hitz F; Kerkhoff A; Greil R; von Tresckow B; Eichenauer DA; Bürkle C; Borchmann S; Fuchs M; Diehl V; Engert A; Borchmann P
    Blood; 2016 May; 127(18):2189-92. PubMed ID: 26834240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
    Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ
    J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.
    Schwenkglenks M; Pettengell R; Szucs TD; Culakova E; Lyman GH
    J Hematol Oncol; 2010 Aug; 3():27. PubMed ID: 20723212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
    Straus DJ; Jung SH; Pitcher B; Kostakoglu L; Grecula JC; Hsi ED; Schöder H; Popplewell LL; Chang JE; Moskowitz CH; Wagner-Johnston N; Leonard JP; Friedberg JW; Kahl BS; Cheson BD; Bartlett NL
    Blood; 2018 Sep; 132(10):1013-1021. PubMed ID: 30049811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study.
    Minuk LA; Monkman K; Chin-Yee IH; Lazo-Langner A; Bhagirath V; Chin-Yee BH; Mangel JE
    Leuk Lymphoma; 2012 Jan; 53(1):57-63. PubMed ID: 21740297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
    Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
    Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Management of older patients with Hodgkin lymphoma: implications of S1826.
    McKenna M; Ryu Tiger YK; Rutherford SC; Evens AM
    Semin Hematol; 2024 Aug; 61(4):236-244. PubMed ID: 38945791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
    Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.
    Rubinstein PG; Moore PC; Rudek MA; Henry DH; Ramos JC; Ratner L; Reid E; Sharon E; Noy A;
    AIDS; 2018 Mar; 32(5):605-611. PubMed ID: 29280762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).
    Ogura M; Itoh K; Kinoshita T; Fukuda H; Takenaka T; Ohtsu T; Kagami Y; Tobinai K; Okamoto M; Asaoku H; Sasaki T; Mikuni C; Hirano M; Chou T; Ohnishi K; Ohno H; Nasu K; Okabe K; Ikeda S; Nakamura S; Hotta T; Shimoyama M
    Int J Hematol; 2010 Dec; 92(5):713-24. PubMed ID: 21076995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
    Chand VK; Link BK; Ritchie JM; Shannon M; Wooldridge JE
    Leuk Lymphoma; 2006 Apr; 47(4):657-63. PubMed ID: 16690524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
    Ogura M; Itoh K; Ishizawa K; Kobayashi Y; Tobinai K; Kinoshita T; Hirano M; Ueda R; Shibata T; Nakamura S; Tsukasaki K; Hotta T; Shimoyama M; Morishima Y;
    Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma.
    Vassilakopoulos TP; Liaskas A; Pereyra P; Panayiotidis P; Angelopoulou MK; Gallamini A
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.